Literature DB >> 14993413

Apolipoprotein E, amyloid, and Alzheimer disease.

K R Bales1, J C Dodart, R B DeMattos, D M Holtzman, S M Paul.   

Abstract

Despite important inroads into the molecular pathology of Alzheimer disease, effective long-term treatment for the condition remains elusive. Among the many gene products that are recognized as factors in the disease is apolipoprotein ( (apoE). The risk that specific isoforms of apoE pose with regard to Alzheimer Disease clearly varies, and so the roles that apoE plays in the brain will be crucial to a full understanding of the disease and to efforts to develop effective therapies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 14993413     DOI: 10.1124/mi.2.6.363

Source DB:  PubMed          Journal:  Mol Interv        ISSN: 1534-0384


  41 in total

Review 1.  Transgenic mouse models of Alzheimer disease: developing a better model as a tool for therapeutic interventions.

Authors:  Masashi Kitazawa; Rodrigo Medeiros; Frank M Laferla
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

2.  The effects of sodium sulfate, glycosaminoglycans, and Congo red on the structure, stability, and amyloid formation of an immunoglobulin light-chain protein.

Authors:  Richard W McLaughlin; Janelle K De Stigter; Laura A Sikkink; Elizabeth M Baden; Marina Ramirez-Alvarado
Journal:  Protein Sci       Date:  2006-06-02       Impact factor: 6.725

Review 3.  Amyloid accomplices and enforcers.

Authors:  Andrei T Alexandrescu
Journal:  Protein Sci       Date:  2004-12-02       Impact factor: 6.725

4.  ApoE and Alzheimer's disease--10 years later.

Authors:  Sara M Mariani
Journal:  MedGenMed       Date:  2004-08-24

Review 5.  Amyloid beta: structure, biology and structure-based therapeutic development.

Authors:  Guo-Fang Chen; Ting-Hai Xu; Yan Yan; Yu-Ren Zhou; Yi Jiang; Karsten Melcher; H Eric Xu
Journal:  Acta Pharmacol Sin       Date:  2017-07-17       Impact factor: 6.150

6.  Statins promote the degradation of extracellular amyloid {beta}-peptide by microglia via stimulation of exosome-associated insulin-degrading enzyme (IDE) secretion.

Authors:  Irfan Y Tamboli; Esther Barth; Leonie Christian; Martin Siepmann; Sathish Kumar; Sandesh Singh; Karen Tolksdorf; Michael T Heneka; Dieter Lütjohann; Patrick Wunderlich; Jochen Walter
Journal:  J Biol Chem       Date:  2010-09-28       Impact factor: 5.157

7.  What does it take to stay healthy past 100?: Commentary on "No disease in the brain of a 115-year-old woman".

Authors:  Joseph L Price
Journal:  Neurobiol Aging       Date:  2008-06-04       Impact factor: 4.673

8.  Localized and efficient curli nucleation requires the chaperone-like amyloid assembly protein CsgF.

Authors:  Ashley A Nenninger; Lloyd S Robinson; Scott J Hultgren
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-08       Impact factor: 11.205

9.  Problems associated with biological markers of Alzheimer's disease.

Authors:  H J Frey; K M Mattila; M A Korolainen; T Pirttilä
Journal:  Neurochem Res       Date:  2005-12       Impact factor: 3.996

Review 10.  The pathogenic implication of abnormal interaction between apolipoprotein E isoforms, amyloid-beta peptides, and sulfatides in Alzheimer's disease.

Authors:  Xianlin Han
Journal:  Mol Neurobiol       Date:  2010-01-07       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.